NCT01592981
Randomised Trial in Waldenstrom's Macroglobulinaemia No drug interventions treatment 2 completed NCT02991638
Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers No drug interventions treatment 3 unknown_status NCT04728893
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) treatment 2 recruiting NCT02180724
An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia treatment 2 active_not_recruiting NCT04952974
B-cell Chronic Lymphoid Malignancies Markers No drug interventions Not Available Not Available unknown_status NCT03771157
Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors supportive_care 0 completed NCT04830137
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies No drug interventions treatment 1 recruiting NCT05131022
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies No drug interventions treatment 1 recruiting NCT03697356
R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's Macroglobulinemia treatment 2 recruiting NCT05979948
A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia treatment 2 recruiting NCT01788020
Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia treatment 3 completed NCT03053440
A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM) No drug interventions treatment 3 completed NCT00398710
A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenström's Macroglobulinemia No drug interventions treatment 2 completed NCT02165397
Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia No drug interventions treatment 3 completed NCT05326308
Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma No drug interventions Not Available Not Available recruiting NCT03332173
Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM) treatment 2 completed NCT06043011
Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms No drug interventions Not Available Not Available recruiting NCT00398372
Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment No drug interventions Not Available Not Available completed NCT06441214
Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval. No drug interventions Not Available Not Available not_yet_recruiting NCT01614821
Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia No drug interventions treatment 2 completed NCT00807677
A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies No drug interventions treatment 1 completed NCT02981745
Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia No drug interventions treatment 1 / 2 unknown_status NCT02604511
Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing treatment 2 completed NCT00481871
Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies No drug interventions treatment 1 / 2 completed NCT00422656
Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia No drug interventions treatment 2 completed NCT02400437
Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia treatment 2 completed NCT00422799
Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM) No drug interventions treatment 2 completed NCT01046006
Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia treatment 2 completed NCT00718419
A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple Myeloma No drug interventions treatment 2 completed NCT00832234
Bortezomib, Dexamethasone, and Rituximab in Untreated Waldenstroms Macroglobulinemia No drug interventions treatment 2 completed NCT00142116
Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia treatment 2 completed NCT00919139
S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS. No drug interventions Not Available Not Available completed NCT02566265
Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients treatment 2 completed NCT00575965
Simvastatin in Waldenstrom's Macroglobulinemia No drug interventions treatment 2 terminated NCT01078974
Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia treatment 1 terminated NCT01177527
Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders No drug interventions Not Available Not Available active_not_recruiting NCT00142129
Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia treatment 2 completed NCT00697346
Study of MLN8237 in Participants With Advanced Hematological Malignancies No drug interventions treatment 1 completed NCT00142155
Correlation of FC Gamma RIIIA Receptor Response in Patients With Waldenstrom's Macroglobulinemia Not Available Not Available completed NCT00146055
Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood No drug interventions treatment 2 completed NCT04274738
A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4 treatment 1 completed NCT00936611
LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia No drug interventions treatment 2 completed NCT01125293
Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia No drug interventions treatment 1 / 2 terminated NCT01647971
Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No drug interventions treatment 1 / 2 completed NCT02092909
Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia No drug interventions treatment 1 / 2 terminated NCT00714259
Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies No drug interventions treatment 2 / 3 terminated NCT00273936
Trial of AVN-944 in Patients With Advanced Hematologic Malignancies Not Available 1 completed NCT03225716
A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia No drug interventions treatment 1 terminated NCT01470196
Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia No drug interventions treatment 2 completed NCT02363439
Extension Study of IMO-8400 in Patients With Waldenström's Macroglobulinemia Who Completed Study 8400-401 No drug interventions treatment 1 / 2 completed NCT02371148
Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia's No drug interventions treatment 2 completed NCT00976248
Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia No drug interventions treatment 2 completed NCT00250926
Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia treatment 2 completed NCT00150462
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies treatment 1 completed NCT00142168
CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia treatment 2 terminated NCT01744912
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies No drug interventions treatment 1 terminated NCT00142181
Phase II Study of Campath-1H Antibody to Treat Waldenstrom's Macroglobulinemia treatment 2 completed NCT00165295
Sildenafil Citrate in Waldenstrom's Macroglobulinemia treatment 2 completed NCT00492050
Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia No drug interventions treatment 2 active_not_recruiting NCT02439138
Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia No drug interventions treatment 2 terminated NCT04840602
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma No drug interventions treatment 2 recruiting NCT04191187
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies treatment 2 active_not_recruiting NCT04195633
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies treatment 2 recruiting NCT04488354
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T No drug interventions other 1 enrolling_by_invitation NCT03884998
Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma treatment 1 active_not_recruiting NCT03335098
Study of VTD in Waldenstrom's Macroglobulinemia treatment 2 unknown_status NCT04279405
A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies No drug interventions treatment 1 completed NCT00719888
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease No drug interventions treatment 2 active_not_recruiting NCT00923507
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL) No drug interventions Not Available Not Available recruiting NCT06340737
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas No drug interventions treatment 1 recruiting NCT00566332
Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia No drug interventions treatment 3 completed NCT03601819
Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders treatment 1 terminated NCT02661035
Allo HSCT Using RIC for Hematological Diseases treatment 2 completed NCT03019666
Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL treatment 1 completed NCT03314974
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders No drug interventions treatment 2 recruiting NCT05176691
HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL No drug interventions treatment 1 withdrawn NCT01163201
T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies No drug interventions treatment 1 / 2 withdrawn NCT04858568
Immune Responses to COVID-19 Vaccination in Lymphoma Patients No drug interventions Not Available Not Available completed NCT02722668
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep No drug interventions treatment 2 active_not_recruiting NCT01314014
Imexon for Relapsed Follicular and Aggressive Lymphomas No drug interventions treatment 2 completed NCT02952508
Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia No drug interventions treatment 2 recruiting NCT03133221
1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation No drug interventions treatment 2 active_not_recruiting NCT02991898
Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies No drug interventions treatment 2 terminated NCT03674411
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy No drug interventions treatment 2 active_not_recruiting NCT01209871
Vaccine Therapy in Treating Patients With Lymphoplasmacytic Lymphoma No drug interventions treatment 1 active_not_recruiting NCT05281809
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia No drug interventions treatment 2 recruiting NCT02652715
Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma No drug interventions basic_science Not Available completed NCT04883437
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas No drug interventions treatment 2 recruiting NCT04799275
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma No drug interventions treatment 2 / 3 recruiting NCT01962636
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases No drug interventions treatment Not Available recruiting NCT05544019
Study of SGR-1505 in Mature B-Cell Neoplasms No drug interventions treatment 1 recruiting NCT01282424
Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas No drug interventions treatment 2 completed NCT03010358
Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma No drug interventions treatment 1 / 2 completed NCT02339922
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma No drug interventions treatment 2 active_not_recruiting NCT04545762
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma No drug interventions treatment 1 recruiting NCT00644189
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma No drug interventions treatment 1 / 2 completed NCT03410901
TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas No drug interventions treatment 1 active_not_recruiting NCT04450069
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies No drug interventions treatment 1 completed NCT01474681
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies No drug interventions treatment 1 / 2 completed NCT00801281
First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. No drug interventions treatment 3 completed NCT03329950
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies No drug interventions treatment 1 completed NCT03679624
Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia treatment 2 terminated NCT04893564
Prognostic Value of Circulating Tumoral DNA After the First 6 Months of Treatment in Patients With Waldenström Macroglobulinemia No drug interventions diagnostic Not Available withdrawn NCT05911802
Prognostic Analyses on a Validation Series of Patients With Waldenström's Disease No drug interventions Not Available Not Available recruiting NCT03952052
Detection of Recurrent Mutations in Waldenström's Disease No drug interventions other Not Available unknown_status NCT02071888
Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors No drug interventions treatment 1 completed NCT00811733
A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia No drug interventions treatment 2 completed NCT03037645
Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers treatment 1 / 2 terminated NCT03833180
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) treatment 1 completed NCT01805375
A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies No drug interventions treatment 1 completed NCT01748721
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma No drug interventions treatment 1 completed NCT00006251
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer treatment 1 / 2 completed NCT04463953
Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia treatment 2 recruiting NCT00890747
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy No drug interventions treatment 1 completed NCT00293345
3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma treatment 1 completed NCT01258998
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma No drug interventions treatment 2 completed NCT00054483
Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction basic_science 1 completed NCT00110071
Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma treatment 1 completed NCT06224309
Preliminary Assessment of [18F]BL40 in PET/CT Scans No drug interventions Not Available Not Available not_yet_recruiting NCT02844309
The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM treatment 4 unknown_status NCT00354185
PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma No drug interventions treatment 1 terminated NCT00068315
Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia treatment 1 completed NCT00025415
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction treatment 1 completed NCT01805037
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas treatment 1 / 2 terminated NCT00118352
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer treatment 2 completed NCT00005799
Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer treatment Not Available completed NCT01815749
Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma No drug interventions treatment 1 active_not_recruiting NCT02213913
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas treatment 1 / 2 active_not_recruiting NCT01384513
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies treatment 2 completed NCT00073918
Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma treatment 2 completed NCT02049541
Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma treatment 1 completed NCT01839916
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies treatment 2 completed NCT05006716
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies No drug interventions treatment 1 / 2 recruiting NCT00078858
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant treatment 1 / 2 completed NCT00014235
Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies treatment Not Available completed NCT02362035
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies treatment 1 / 2 active_not_recruiting NCT01158274
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors treatment 1 completed NCT02933320
BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia treatment 1 / 2 completed NCT00058227
Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma treatment 1 completed NCT00089076
MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma treatment 1 / 2 terminated NCT00098891
MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas treatment 1 completed NCT03187262
A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia treatment 2 completed NCT00101244
SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma treatment 1 terminated NCT00058240
Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma treatment 1 / 2 completed NCT01536067
Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia No drug interventions treatment 2 terminated NCT00049504
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer treatment 2 completed NCT00891072
Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery No drug interventions treatment 1 completed NCT00064246
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder treatment 1 / 2 completed NCT00040846
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies treatment 2 completed NCT00003210
Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease treatment 2 completed NCT00017381
Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma treatment 0 completed NCT00088881
Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma treatment 2 terminated NCT00005950
506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma treatment 2 terminated NCT01678443
Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies No drug interventions treatment 1 terminated NCT01408043
Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma No drug interventions treatment Not Available terminated NCT02281279
Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma No drug interventions treatment 1 / 2 withdrawn NCT02640287
Expression of Ku70/XRCC6 in Waldenström's Macroglobulinemia No drug interventions other Not Available completed NCT00918333
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma No drug interventions treatment 1 / 2 completed NCT04052854
A Single-Arm, Expanded Access Study of Zanubrutinib in Participants With B-cell Malignancies Not Available Not Available no_longer_available NCT01959477
Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant No drug interventions treatment 0 completed NCT01044745
Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer No drug interventions treatment 2 terminated NCT00012298
Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma treatment 1 / 2 terminated NCT00096005
Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas treatment 1 terminated NCT01812005
Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma No drug interventions treatment 2 terminated NCT02844361
Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia No drug interventions treatment 4 unknown_status NCT01769911
Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma No drug interventions treatment Not Available withdrawn NCT00089011
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer treatment 2 completed NCT00499811
Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction No drug interventions treatment 1 completed NCT00112593
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer treatment Not Available completed NCT00089271
17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas treatment 1 completed NCT00856388
Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders No drug interventions treatment Not Available completed NCT00769288
FAU in Treating Patients With Advanced Solid Tumors or Lymphoma No drug interventions treatment 1 completed NCT02168907
CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma No drug interventions treatment 1 terminated NCT02037256
Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma No drug interventions treatment Not Available completed NCT00348985
PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas No drug interventions treatment 1 completed NCT01588015
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant No drug interventions supportive_care 1 completed NCT00621452
Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma No drug interventions treatment 1 completed NCT00118170
Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function treatment 1 completed NCT00601718
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma No drug interventions treatment 1 / 2 completed NCT01231919
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia No drug interventions treatment 1 completed NCT01658319
Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies No drug interventions treatment 1 completed NCT00003196
Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma treatment Not Available completed NCT01110135
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma No drug interventions treatment 2 completed NCT00005786
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia treatment Not Available terminated NCT00054639
Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma treatment 2 completed NCT02844322
The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia No drug interventions treatment 4 unknown_status NCT01769222
Ipilimumab and Local Radiation for Selected Solid Tumors No drug interventions treatment 1 terminated NCT00458731
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma No drug interventions treatment 1 completed NCT05294731
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader No drug interventions treatment 1 / 2 recruiting NCT00006473
Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma treatment 2 completed NCT00867529
Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma No drug interventions treatment 2 completed NCT00119392
Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma treatment 2 completed NCT00062244
Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia No drug interventions treatment 1 / 2 completed NCT00288067
Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma No drug interventions treatment 1 / 2 terminated NCT00536601
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors No drug interventions treatment Not Available completed NCT00290472
CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia treatment 2 completed NCT00103272
17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer treatment 1 terminated NCT01427881
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies No drug interventions treatment 2 completed NCT01419795
Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant No drug interventions treatment 2 terminated NCT01652014
Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies No drug interventions treatment 2 withdrawn NCT01789255
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies No drug interventions supportive_care 2 completed NCT00112723
Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma treatment 1 / 2 terminated NCT03620903
Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia No drug interventions treatment 2 active_not_recruiting NCT00113802
Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia treatment 2 terminated NCT00082784
Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms treatment 1 completed NCT02916979
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG No drug interventions treatment 1 completed NCT05065554
ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy treatment 2 recruiting NCT01116154
Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma treatment 1 terminated NCT04898647
Clinical Study of the Hyperviscosity Syndrome in Waldenström Macroglobulinemia No drug interventions diagnostic Not Available recruiting NCT06561347
Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM treatment 2 not_yet_recruiting NCT04775745
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. No drug interventions treatment 1 recruiting NCT04043845
ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies treatment 1 withdrawn NCT00608361
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery No drug interventions treatment 1 completed NCT00096161
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant treatment 2 completed NCT01045928
Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma treatment 1 terminated NCT01129193
AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma treatment 1 completed NCT01177371
High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma treatment 2 completed NCT05020678
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers No drug interventions treatment 1 recruiting NCT01254578
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers treatment 1 completed NCT01567709
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma treatment 1 completed NCT04665115
Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19) treatment 2 withdrawn NCT04702932
Establishment of Genomic, Transcriptomic and Functional Characteristics of Tumor Cells in Hyperinflammatory Hemopathies No drug interventions Not Available Not Available not_yet_recruiting NCT03269552
Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma treatment 2 terminated NCT01479842
Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma treatment 1 active_not_recruiting NCT03162536
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) treatment 1 / 2 active_not_recruiting NCT05003141
PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies No drug interventions treatment 1 unknown_status NCT01272817
Nonmyeloablative Allogeneic Transplant No drug interventions treatment Not Available completed NCT04260217
APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia treatment 1 completed NCT02669017
Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) treatment 1 completed NCT02677324
Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia treatment 2 completed NCT02298816
B-Cell Hematologic Malignancy Vaccination Registry No drug interventions Not Available Not Available withdrawn NCT03521596
Non-invasive Diagnostics and Monitoring of MRD and Clonal Evolution in Waldenström's Macroglobulinemia and in IgM-MGUS No drug interventions Not Available Not Available active_not_recruiting NCT01351935
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia treatment 1 completed NCT05602363
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma No drug interventions treatment 1 recruiting NCT01093586
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies treatment 2 completed NCT01804686
A Long-term Extension Study of PCI-32765 (Ibrutinib) treatment 3 enrolling_by_invitation NCT03333486
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer treatment 2 active_not_recruiting NCT06151730
Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study No drug interventions Not Available Not Available recruiting NCT04062448
A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM) treatment 2 completed NCT04018248
BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I) treatment 1 active_not_recruiting NCT06547866
Study Evaluating the Efficacy and Tolerance of a Zanubrutinib and BGB-11417 Combination in Patients Previously Treated for Waldenström Macroglobulinemia treatment 2 not_yet_recruiting NCT01529827
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies treatment 2 completed NCT01813227
A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531 treatment 2 completed NCT00789776
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer No drug interventions treatment 1 / 2 completed NCT00039676
Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer No drug interventions Not Available Not Available active_not_recruiting NCT02086591
A Phase II Study of Doxycycline in Relapsed NHL treatment 2 terminated NCT06510491
Epcoritamab in Previously Treated WM treatment 2 not_yet_recruiting NCT05914662
Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM treatment 2 recruiting NCT01199562
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant Not Available Not Available completed NCT01118689
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia No drug interventions treatment 1 completed NCT01779167
Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia No drug interventions treatment 2 terminated NCT02962401
Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia No drug interventions treatment 2 completed NCT04830046
Covid-19 Vaccine Responsiveness in MM and Waldenstrom No drug interventions Not Available Not Available unknown_status NCT00003512
Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia treatment 2 withdrawn NCT01231412
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant No drug interventions treatment 3 completed NCT00861510
A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies No drug interventions treatment 1 completed NCT05734495
Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia No drug interventions treatment 2 recruiting NCT03679455
A Study of Obinutuzumab (RO5072759) Induction in Patients With Relapsed/ Refractory Waldenström Macroglobulinemia, OBI-1 No drug interventions treatment 2 unknown_status NCT06084650
Optical Coherence Tomography (OCT) and OCT Angiography(OCTA) Deep Learning in Waldenström's Macroglobulinemia Patients No drug interventions Not Available Not Available completed NCT01523223
Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies No drug interventions treatment 1 completed NCT00777738
Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia No drug interventions treatment 2 completed NCT01076543
Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma No drug interventions treatment 1 / 2 completed NCT01075321
Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma No drug interventions treatment 1 / 2 completed NCT05640102
Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia No drug interventions Not Available Not Available recruiting NCT01326702
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors No drug interventions treatment 1 / 2 completed NCT04028479
The Registry of Oncology Outcomes Associated With Testing and Treatment No drug interventions Not Available Not Available recruiting NCT05093153
Spanish Registry of Patients With IgM Monoclonal Gammopathies No drug interventions Not Available Not Available recruiting NCT01261247
Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma No drug interventions treatment 2 completed NCT05024045
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers No drug interventions treatment 1 active_not_recruiting NCT01527045
Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies No drug interventions prevention 2 completed NCT05190705
Loncastuximab Tesirine in WM No drug interventions treatment 2 recruiting NCT03192397
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant No drug interventions treatment 1 / 2 active_not_recruiting NCT01416428
Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies No drug interventions treatment 1 / 2 terminated NCT00711828
Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma No drug interventions treatment 2 completed NCT05099471
Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia No drug interventions treatment 2 not_yet_recruiting NCT00075478
Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer treatment 3 completed NCT00083707
Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia treatment 2 completed NCT05952037
Study to Evaluate the Efficacy and Safety of Sonrotoclax in Participants With Waldenström's Macroglobulinemia No drug interventions treatment 2 recruiting NCT04116437
Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment No drug interventions treatment 2 recruiting NCT04464200
19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers No drug interventions treatment 1 active_not_recruiting NCT05172700
Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer No drug interventions Not Available Not Available available NCT04115059
Dasatinib In Waldenström Macroglobulinemia No drug interventions treatment 1 terminated NCT01251575
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant No drug interventions treatment 2 completed NCT03630042
Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia No drug interventions treatment 2 completed NCT02257242
Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma No drug interventions treatment 1 completed NCT04624906
Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia No drug interventions treatment 2 active_not_recruiting NCT03820817
Rifaximin in Patients With Monoclonal Gammopathy No drug interventions treatment 1 recruiting NCT02109224
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection No drug interventions treatment 1 terminated NCT04072458
A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies No drug interventions treatment 1 recruiting NCT00720135
Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma No drug interventions treatment 1 completed NCT04273139
Ibrutinib + Venetoclax in Untreated WM treatment 2 active_not_recruiting NCT01273766
Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies No drug interventions supportive_care 2 completed NCT03364231
Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma No drug interventions treatment 2 completed NCT03506373
Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia No drug interventions treatment 2 active_not_recruiting NCT04042376
A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM) treatment 4 completed NCT01008462
Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia No drug interventions treatment 2 completed NCT04263480
Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia No drug interventions treatment 2 recruiting NCT00438880
Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma No drug interventions treatment 1 / 2 completed NCT02332980
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas No drug interventions treatment 2 completed NCT03740529
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL No drug interventions treatment 1 / 2 active_not_recruiting NCT02269592
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome No drug interventions Not Available Not Available recruiting NCT00783367
Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas No drug interventions treatment 2 completed NCT00105001
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer treatment 2 completed NCT01109069
Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia No drug interventions treatment 2 completed NCT02302469
Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia No drug interventions treatment 1 / 2 completed NCT04061512
Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia treatment 2 / 3 recruiting NCT00072514
Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies treatment 2 completed NCT00107614
DT PACE, Tandem Autologous Transplant, Maintenance Therapy for Waldenstrom's Macroglobulinemia Patients treatment 2 terminated NCT00244855
Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma treatment 2 completed